Movement Alert|GeneDx Holdings Falls 5.28% in Regular Trading, Cautious outlook and target price cuts keep pressure on shares

Market Focus11-13

On November 13, GeneDx Holdings fell 5.28% in Regular Trading, trading at $49.525 per share, with turnover of $10.245 million.

The move appears tied to continued post-earnings digestion of the company’s cautious forward outlook, alongside analyst target price reductions despite some maintained buy ratings.

GeneDx Holdings reported third-quarter adjusted EPS of $0.28 on revenue of $123.1 million, ahead of consensus expectations of $0.07 and $122.9 million, respectively. However, the company guided fourth-quarter revenue to $135.0 million versus expectations of $142.6 million and reiterated full-year revenue of $475 million to $490 million, compared with consensus of $482.3 million. After the report, Piper Sandler maintained a buy rating with a $95 target, while BTIG cut its target to $85 from $90 and Jefferies reduced its target to $80 from $100, reflecting a more cautious view on near-term growth cadence.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment